Evaxion A/Sは2026年3月5日、2025年通期の財務結果を発表し、売上高750万ドルに対する純損失770万ドル（前年比縮小）を報告した。臨床段階のバイオテクノロジー企業は、2025年の主要マイルストーンを強調し、MSDとの大型ライセンス契約と個別化がんワクチンEVX-01の強力な第2相データを挙げた。現金残高2320万ドルは2027年末まで運用可能期間を延長する。
Evaxion A/Sは、デンマーク・コペンハーゲンを拠点とする臨床段階のTechBio企業で、2026年3月5日に事業更新および2025年通期の財務結果を公表し、2025年を変革の年と位置づけた。同社は2025年の純損失を770万ドルと報告し、前年比290万ドルの改善となった。これは売上高の増加と運用費の低下によるものだ。売上高は合計750万ドルで、MSDからの感染症ワクチンEVX-B3のオプション行使手数料750万ドルとGates Foundationの助成金による。
AIによるレポート AIによって生成された画像
Tesla reported a 46% drop in 2025 full-year profits to $3.8 billion—the first annual revenue decline—due to falling vehicle deliveries, competition, and lost EV tax credits. Despite Q4 challenges, it beat earnings estimates, unveiled a strategic shift to 'physical AI' including scrapping Model S/X production, launching TerraFab chip factory, ramping robotaxis and Optimus robots, and planning $20B+ capex, fueling analyst optimism and a forward P/E ratio of 196 versus auto peers.
SRx Health Solutions Inc. announced its fiscal first quarter 2026 results, showing net sales of $2.8 million and a net loss of $8.6 million for the period ended December 31, 2025. The company deployed $18 million into Bitcoin and Ethereum as part of a digital treasury strategy and entered a definitive agreement to acquire EMJ Crypto Technologies. The acquisition is expected to close in the first half of 2026.
AIによるレポート
ImmunityBio, Inc. conducted its full year 2025 earnings conference call on March 3, 2026, at 4:30 PM EST. The call featured company leaders and analysts, with a standard disclaimer on forward-looking statements. A replay is available on the company's investor relations website.
IonQ announced Q4 revenue of $61.9 million, a 429% increase year-over-year, accounting for nearly half of its 2025 total revenue. The company also saw remaining performance obligations rise to $370 million, up from $77 million the previous year. This performance highlights growing commercial demand for its quantum computing technology.
AIによるレポート
A Seeking Alpha analyst has upgraded TransMedics (NASDAQ:TMDX) to Strong Buy, citing expected revenue growth of around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. The firm is seen as over the peak of its capital expenditure cycle, with margins targeting 30% by 2028. The analyst holds a long position in the stock.
Immunocore Holdings plc has released a slide deck for its 2025 fourth-quarter earnings call. The presentation accompanies the company's financial results discussion. It was published on February 25, 2026.
AIによるレポート
Compañía Sudamericana de Vapores (CSAV), part of Grupo Luksic, reported profits of US$213.1 million for 2025, down 45% from 2024. The decline stems mainly from lower results at its key investment Hapag-Lloyd, due to reduced freight rates and higher operating costs.